CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 275 enrolled
Drug / intervention
doxepin hydrochloride oral solution +2 moredrug
Likely dose
doxepin hydrochloride oral solution 2.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02229539
NCT02229539Phase 3Completed

A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

Alliance for Clinical Trials in Oncology·interventional·Posted Sep 1, 2014·Updated May 18, 2025

In Brief

A Phase 3 clinical trial evaluating doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, and 1 other intervention for Acute Oral Mucositis Pain. Completed, enrolled 275 participants across 350 sites.

Detailed Summary

The purpose of this study is to test whether a mouthwash made with a drug called doxepin can reduce the pain caused by mouth sores resulting from radiation therapy. A number of mouth rinse preparations exist for patients with treatment-related oral mucositis pain such as the DLA rinse, an over-the-counter medication. This study will evaluate the effects of doxepin compared to DLA (diphenhydramine, lidocaine and antacids) and placebo.Doxepin is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety, long-term pain management, as well as management of rash.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 1, 2014
Enrollment StartNov 18, 2014
Primary CompletionMay 23, 2016
Study CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.8 years ago

Interventions

doxepin hydrochloride oral solutiondrug

2.5 mL (25 mg) doxepin and 2.5 mL water administered orally

DLA (diphenhydramine, lidocaine and antacids) rinsedrug

5.0 mL administered orally

Placeboother

2.5 mL placebo and 2.5 mL water administered orally